Search for Clinical Trial Results

Sponsored By

Lymphatic Malformations - 25 Studies Found

Status Study
Terminated Study Name: Selenium in the Treatment of Complicated Lymphatic Malformations
Condition: Lymphatic Malformations
Date: 2010-09-24
Interventions: Drug: Selenium 400 μg once a day for 6 months by mouth
Completed Study Name: Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations
Condition: Lymphatic Malformations
Date: 2001-02-02
Interventions: Drug: picibanil Up to .2 mg per injection, given intralesionally every 6-8 weeks
Completed Study Name: A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Condition: Lymphangioma
Date: 2011-02-03
Interventions: Drug: Sildenafil Sildenafil oral tablet three times daily
Recruiting Study Name: Sildenafil for the Treatment of Lymphatic Malformations
Condition:
  • Lymphatic Malformations
  • Lymphatic Diseases

Date: 2015-01-07
Interventions:
  • Drug: Sildenafil 20 mg tablets
  • Other: Plac
Active, not recruiting Study Name: Airway Vascular Lesions
Condition:
  • Hemangiomas
  • Venous Malformations
  • Lym
    Date: 2007-12-17
    Interventions: Other: Protocols for Treatment Determine protocols for treatment of airway vascular malformation and to
Recruiting Study Name: Lymphatic Anomalies Registry
Condition:
  • Lymphatic Malformation
  • Generalized Lymphatic Anomaly (GLA)

    • Date: 2015-03-17
Completed Study Name: Diagnosis of Hemangiomas and Vascular Malformations
Condition:
  • Hemangiomas
  • Vascular Malformations
  • Venular Malformations Date: 2007-12-18
Active, not recruiting Study Name: Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Condition:
  • Kaposiform Hemangioendotheliomas
  • Tufted Angioma
  • Capillary
    Date: 2009-09-10
    Interventions: Drug: sirolimus liquid dosing based on trough levels
Completed Study Name: Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
Condition: Vascular Anomalies
Date: 2005-12-02
Interventions: Drug: Marimastat
Completed Study Name: Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
Condition: 22q11.2 Deletion Syndrome
Date: 2016-08-29
Interventions: Drug: NFC-1 Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard g
Next >>>